These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6376650)

  • 21. [Construction of recombinant plasmids encoding the biosynthesis of the beta-subunit of cholera toxin].
    Ianishevskiĭ NV; Gintsburg AL; Vertiev IuV; Demme EIu; Karataev GI
    Mol Gen Mikrobiol Virusol; 1987 Apr; (4):26-32. PubMed ID: 3037359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization and Genetic Variation of Vibrio cholerae Isolated from Clinical and Environmental Sources in Thailand.
    Siriphap A; Leekitcharoenphon P; Kaas RS; Theethakaew C; Aarestrup FM; Sutheinkul O; Hendriksen RS
    PLoS One; 2017; 12(1):e0169324. PubMed ID: 28103259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microbes and microbial Toxins: paradigms for microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin.
    Lencer WI
    Am J Physiol Gastrointest Liver Physiol; 2001 May; 280(5):G781-6. PubMed ID: 11292584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation into immunological responses against a native recombinant CTB whole-cell Vibrio cholerae vaccine in a rabbit model.
    Boustanshenas M; Bakhshi B; Ghorbani M
    J Appl Microbiol; 2013 Feb; 114(2):509-15. PubMed ID: 23082752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains.
    Benítez JA; Silva AJ; Rodríguez BL; Fando R; Campos J; Robert A; García H; García L; Pérez JL; Oliva R; Torres CA; Ledón T
    Arch Med Res; 1996; 27(3):275-83. PubMed ID: 8854382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic diversity and virulence potential of environmental Vibrio cholerae population in a cholera-endemic area.
    Faruque SM; Chowdhury N; Kamruzzaman M; Dziejman M; Rahman MH; Sack DA; Nair GB; Mekalanos JJ
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2123-8. PubMed ID: 14766976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine.
    Pierce NF; Kaper JB; Mekalanos JJ; Cray WC; Richardson K
    Infect Immun; 1987 Feb; 55(2):477-81. PubMed ID: 3804447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
    Carrada-Bravo T
    Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent progress in cholera vaccination.
    Pierre PG; Lucas G; Van Damme M; Vaerman JP
    Acta Gastroenterol Belg; 1992; 55(5-6):430-6. PubMed ID: 1288041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic, molecular, and immunologic aspects of Vibrio cholerae infection].
    Fica AE; Cabello FC
    Rev Med Chil; 1993 Mar; 121(3):312-20. PubMed ID: 8248646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholera toxin and related enterotoxins: a cell biological and immunological perspective.
    de Haan L; Hirst TR
    J Nat Toxins; 2000 Aug; 9(3):281-97. PubMed ID: 10994530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of disease and immunity in cholera: a review.
    Holmgren J; Svennerholm AM
    J Infect Dis; 1977 Aug; 136 Suppl():S105-12. PubMed ID: 197173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular analysis of Vibrio cholerae O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates.
    Singh DV; Matte MH; Matte GR; Jiang S; Sabeena F; Shukla BN; Sanyal SC; Huq A; Colwell RR
    Appl Environ Microbiol; 2001 Feb; 67(2):910-21. PubMed ID: 11157262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure and arrangement of the cholera toxin genes in Vibrio cholerae O139.
    Lebens M; Holmgren J
    FEMS Microbiol Lett; 1994 Apr; 117(2):197-202. PubMed ID: 8181723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.
    Sanchez J; Holmgren J
    Proc Natl Acad Sci U S A; 1989 Jan; 86(2):481-5. PubMed ID: 2492108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T
    Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possibilities of immunization against cholera and related enterotoxic enteropathies.
    Finkelstein RA
    Dev Biol Stand; 1976; 33():102-7. PubMed ID: 955264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions.
    Fasano A; Baudry B; Pumplin DW; Wasserman SS; Tall BD; Ketley JM; Kaper JB
    Proc Natl Acad Sci U S A; 1991 Jun; 88(12):5242-6. PubMed ID: 2052603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.